HUP0401156A2 - Májfibrózis kezelésére szolgáló módszerek - Google Patents

Májfibrózis kezelésére szolgáló módszerek

Info

Publication number
HUP0401156A2
HUP0401156A2 HU0401156A HUP0401156A HUP0401156A2 HU P0401156 A2 HUP0401156 A2 HU P0401156A2 HU 0401156 A HU0401156 A HU 0401156A HU P0401156 A HUP0401156 A HU P0401156A HU P0401156 A2 HUP0401156 A2 HU P0401156A2
Authority
HU
Hungary
Prior art keywords
methods
liver fibrosis
treating liver
liver
reducing
Prior art date
Application number
HU0401156A
Other languages
English (en)
Inventor
Henry H. Hsu
Original Assignee
Intermune, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune, Inc. filed Critical Intermune, Inc.
Publication of HUP0401156A2 publication Critical patent/HUP0401156A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A jelen találmány a májfibrózis csökkentésére, a májfibrózisbanszenvedő egyén májfunkcióinak fokozására és a májcirrhozissalkapcsolatos komplikációk előfordulásának csökkentésére szolgálómódszerekkel kapcsolatos. A módszerek általánosságban magukbafoglalják az IFN-l terápiásan hatékony mennyiségének alkalmazását. Ó
HU0401156A 2001-07-20 2002-07-09 Májfibrózis kezelésére szolgáló módszerek HUP0401156A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30701301P 2001-07-20 2001-07-20
PCT/US2002/021813 WO2003007981A1 (en) 2001-07-20 2002-07-09 Methods of treating liver fibrosis

Publications (1)

Publication Number Publication Date
HUP0401156A2 true HUP0401156A2 (hu) 2004-12-28

Family

ID=23187860

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401156A HUP0401156A2 (hu) 2001-07-20 2002-07-09 Májfibrózis kezelésére szolgáló módszerek

Country Status (15)

Country Link
US (1) US20040241138A1 (hu)
EP (1) EP1416953A4 (hu)
JP (1) JP2004535464A (hu)
KR (1) KR20040019069A (hu)
CN (1) CN1549724A (hu)
AR (1) AR047191A1 (hu)
BR (1) BR0211336A (hu)
CA (1) CA2453475A1 (hu)
HU (1) HUP0401156A2 (hu)
IL (1) IL159784A0 (hu)
MX (1) MXPA04000630A (hu)
NO (1) NO20040253L (hu)
PL (1) PL367415A1 (hu)
WO (1) WO2003007981A1 (hu)
ZA (1) ZA200400319B (hu)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20050069546A1 (en) * 2003-09-30 2005-03-31 Yaron Ilan Educated NKT cells and their uses in the treatment of immune-related disorders
US7655254B2 (en) 2005-02-03 2010-02-02 Intarcia Therapeutics, Inc. Implantable device for continuous delivery of interferon
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2008011216A2 (en) 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
AU2007284759B2 (en) 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
AU2008244523B2 (en) 2007-04-23 2012-02-16 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
RU2547990C2 (ru) 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
MX360979B (es) * 2011-09-16 2018-11-22 Galectin Therapeutics Inc Composiciones de galacto-ramnogalacturonato para el tratamiento de la esteatohepatitis no alcohólica y de la enfermedad del higado graso no alcohólico.
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
UY34402A (es) 2011-10-21 2013-05-31 Abbvie Inc Métodos para el tratamiento de hcv
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
CN104619329B (zh) 2012-06-06 2018-01-26 卡莱克汀医疗有限公司 用于治疗与升高的诱导型一氧化氮合酶相关联的疾病的半乳糖‑鼠李糖半乳糖醛酸酯组合物
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
EP3302354B1 (en) 2015-06-03 2023-10-04 i2o Therapeutics, Inc. Implant placement systems
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
RU2760007C2 (ru) 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Полипептиды, селективные к рецепторам глюкагона, и способы их применения
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL76591A0 (en) * 1984-10-05 1986-02-28 Bioferon Biochem Substanz Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof
US5362490A (en) * 1986-07-25 1994-11-08 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Human myelomonocyte interferon-gamma, and process for preparation and use thereof
AU2855189A (en) * 1988-01-25 1989-07-27 Baker Cummins Dermatologicals, Inc. Method of treating fibrotic disorders
WO2001023006A1 (en) * 1999-09-28 2001-04-05 Amarillo Biosciences, Inc. Low dose ifn-gamma for treatment of disease
US7129222B2 (en) * 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof

Also Published As

Publication number Publication date
ZA200400319B (en) 2005-03-30
BR0211336A (pt) 2004-09-28
KR20040019069A (ko) 2004-03-04
JP2004535464A (ja) 2004-11-25
PL367415A1 (en) 2005-02-21
MXPA04000630A (es) 2005-02-17
CA2453475A1 (en) 2003-01-30
NO20040253L (no) 2004-03-19
AR047191A1 (es) 2006-01-11
IL159784A0 (en) 2004-06-20
CN1549724A (zh) 2004-11-24
EP1416953A4 (en) 2005-11-09
WO2003007981A1 (en) 2003-01-30
EP1416953A1 (en) 2004-05-12
US20040241138A1 (en) 2004-12-02

Similar Documents

Publication Publication Date Title
HUP0401156A2 (hu) Májfibrózis kezelésére szolgáló módszerek
GB2392525B (en) Using digital signatures to streamline the process of amending financial transactions
AU2003220205A8 (en) Ethanol-diesel fuel composition and methods thereof
AU2002355419A1 (en) Methods and compositions for treating diseases associated with excesses in ace
AU2003271923A8 (en) Facilitating and authenticating transactions
CA97703S (en) Toothbrush handle
MY135721A (en) Amidino compounds useful as nitric oxide synthase inhibitors
NO20052469D0 (no) Inhibitorer av II-beta-hydroksysteroid-dehydrogenase type 1 og type 2.
AU2003286492A1 (en) Magnetic substrates, composition and methods of making the same
GB0126990D0 (en) Method and composition for improving fuel consumption
EP1314794A4 (en) SOFT METAL AND MANUFACTURING METHOD, DECORATIVE ITEMS AND MANUFACTURING METHOD THEREFOR
EP1453837A4 (en) TARGETED THERAPEUTIC AGENTS AND USES THEREOF
MY131964A (en) 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
WO2004103296A3 (en) Methods of treating idiopathic pulmonary fibrosis
GB2396707B (en) Facilitating and authenticating transactions
WO2004031352A3 (en) Interferon variants with improved properties
GB2386906B (en) Heat-resisting steel and method of manufacturing the same
HUP0302233A2 (hu) Virális betegségek kezelésére IL-18-cal és IL-18 kombinációkkal
GB2389854B (en) Release films
CA96874S (en) Set of flatware
EP1572086A4 (en) METHODS AND COMPOSITION BASED ON THE DISCOVERY OF METABOLISM OF NITROGLYCERIN
AU2002322515A1 (en) Compositions, methods, and kits related to treating and diagnosing hypertension
WO2004006864A3 (en) Methods and compositions for the enhancement of wound healing
EP1401324A4 (en) SURGICAL METALS WITH IMPROVED HARDNESS AND METHOD FOR THE PRODUCTION THEREOF
CA96875S (en) Set of flatware

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees